Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis

Nima Mowzoon, Alyssa Sussman, Walter G. Bradley

Research output: Contribution to journalArticle

116 Scopus citations


We report favorable results of the long term use of mycophenolate in the treatment of three patients with myasthenia gravis (MG), two patients with chronic inflammatory demyelinating polyneuropathy (CIDP), one patient with secondary polymyositis (PM), and one patient with inclusion body myositis (IBM). Side effects were mild. Mycophenolate appears to be a useful addition to the armamentarium of immunosuppressants for treatment of chronic immunologically mediated neuromuscular diseases.

Original languageEnglish (US)
Pages (from-to)119-122
Number of pages4
JournalJournal of the Neurological Sciences
Issue number2
StatePublished - Apr 1 2001



  • Chronic inflammatory demyelinating polyneuropathy
  • Inclusion body myositis
  • Myasthenia gravis
  • Mycophenolate
  • Polymyositis
  • Therapy

ASJC Scopus subject areas

  • Aging
  • Clinical Neurology
  • Surgery
  • Developmental Neuroscience
  • Neurology
  • Neuroscience(all)

Cite this